60 DEGREES PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.0M | $607.6K | $253.6K | $223.2K |
| Cost of Revenue | $781.7K | $384.8K | $474.6K | $432.4K |
| Gross Profit | $223.8K | $222.8K | $-221.0K | $-209.2K |
| Gross Margin | 22.3% | 36.7% | -87.1% | -93.7% |
| Operating Expenses | ||||
| Research & Development | $2.1M | $5.0M | $691.8K | $525.6K |
| SG&A Expense | $6.3M | $5.0M | $4.2M | $1.3M |
| Operating Income | $-7.8M | $-9.7M | $-5.2M | $-1.8M |
| Operating Margin | -771.6% | -1,599.0% | -2,032.8% | -784.2% |
| Interest Expense | — | $0 | $2.3M | $4.0M |
| Pretax Income | $-7.4M | $-8.0M | $-3.8M | $-6.2M |
| Income Tax Expense | $0 | $0 | $250 | $500 |
| Net Income | $-7.4M | $-7.9M | $-3.8M | $-6.2M |
| Net Margin | -732.5% | -1,308.0% | -1,485.1% | -2,769.5% |
| EPS (Basic) | $-11.73 | $-12.36 | $-9.86 | $-0.44 |
| EPS (Diluted) | $-11.73 | $-12.36 | $-9.86 | $-0.44 |
| Shares Outstanding (Basic) | 670.2K | 682.0K | 397.9K | 14.2M |
| Shares Outstanding (Diluted) | 670.2K | 682.0K | 397.9K | 14.2M |
| Dividends Per Share | — | — | — | — |